IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.
- Conditions
- Chronic Constipation
- Interventions
- First Posted Date
- 2005-11-18
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 88
- Registration Number
- NCT00255372
- Locations
- 🇹🇭
Ramathibodi Hospital, Mahidol University,, Bangkok, Thailand
🇹🇭Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand
Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
- Conditions
- Lateral Canthal Lines
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 221
- Registration Number
- NCT00247559
- Locations
- 🇬🇧
The Cambridge Private Hospital, Cambridge, England, United Kingdom
🇬🇧Harley Street, London, England, United Kingdom
🇩🇪Universitats - Hautklinik, Homburg, Germany
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
- Conditions
- Low Back Pain
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 35
- Registration Number
- NCT00246155
- Locations
- 🇰🇷
Wooridul Spine Hospital, Seoul, Korea, Republic of
A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.
- Conditions
- Myofascial Pain Syndromes
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 76
- Registration Number
- NCT00246142
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
- Conditions
- Muscle SpasticityCerebrovascular Accident
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 162
- Registration Number
- NCT00234546
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, Hong Kong
🇹🇭Siriraj Hospital, Bangkok, Thailand
🇲🇾University Hospital of Malaya Medical Centre, Kuala Lumpur, Malaysia
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT00234572
- Locations
- 🇺🇸
Pituitary Center, Los Angeles, California, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Northwestern Medical Facility, Chicago, Illinois, United States
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
- Conditions
- Acromegaly
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 225
- Registration Number
- NCT00234520
- Locations
- 🇮🇹
University "Federico II" of Naples, Naples, Italy
🇧🇪Cliniques Universitaires Saint Luc, Bruxelles, Belgium
🇧🇪CHU de Liege, Liege, Belgium
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
- Conditions
- DwarfismTurner SyndromePituitary DiseasesRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 251
- Registration Number
- NCT00234533
- Locations
- 🇧🇪
Dienst Kindergeneeskunde, Edegem, Belgium
🇬🇧University Hospital Wales, Cardiff, Wales, United Kingdom
🇫🇷Centre Hospitalier General, Le Havre, France
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
- Conditions
- Blepharospasm
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 120
- Registration Number
- NCT00234507
- Locations
- 🇺🇸
Neurological Institute, Phoenix, Arizona, United States
🇺🇸Plastic Eye Surgery Association, Pensacola, Florida, United States
🇺🇸Columbia-Presbyterian Medical Center, New York, New York, United States
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
- Conditions
- Muscle SpasticityCerebrovascular Accident
- Interventions
- Biological: Botulinum toxin type ADrug: Placebo
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 96
- Registration Number
- NCT00216411
- Locations
- 🇦🇺
St Josephs Hospital, Auburn, New South Wales, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia